Solanezumab

ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline

Retrieved on: 
Monday, July 17, 2023
Volunteering, PMN, Plaque, Therapy, PROMIS, AAN, Pharmacokinetics, American Academy, Multiple system atrophy, Solanezumab, QS-21, Antibody, Incidence, Meningoencephalitis, AAIC, ARIA, Patient, Immunoglobulin G, MSA, Risk, Poster, Neuroscience, Epitope, TSX, Abo, Surface plasmon resonance, FDA, American Academy of Neurology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, ALS, IND, Food, Safety, Conference, Vaccine, Pharmaceutical industry, Paint, Publication

Additionally, the Company presented preclinical mouse studies that further characterize a computationally-derived AD vaccine directed at AβO.

Key Points: 
  • Additionally, the Company presented preclinical mouse studies that further characterize a computationally-derived AD vaccine directed at AβO.
  • The data were presented in posters on July 16, 2023, at the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam, Netherlands.
  • “The increasingly recognized benefit of targeting oligomers of Aβ underscores the potential advantage of our PMN310 antibody and AβO vaccine candidates.
  • ProMIS presented a poster on its vaccine candidate being evaluated preclinically for the prevention of AD at AAIC.

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

Retrieved on: 
Wednesday, March 29, 2023
Amyloid-related imaging abnormalities, PMN, Plaque, Therapy, PROMIS, Multiple system atrophy, Solanezumab, Brain, Antibody, Dementia, DSM-IV codes, ARIA, International Conference on Information Systems Security and Privacy, Patient, MSA, Donanemab, Neuron, Risk, Neuroscience, Crenezumab, TSX, ALS, IND, Conference, Vaccine

Antibody therapies that target Aβ in AD continue to generate interest with recent approvals and new potential treatments in development.

Key Points: 
  • Antibody therapies that target Aβ in AD continue to generate interest with recent approvals and new potential treatments in development.
  • However, it has been a challenge to specifically target toxic oligomers since they are the least abundant form of Aβ in the brain.
  • In preclinical studies, ProMIS Neurosciences’ lead candidate, PMN310, has demonstrated its ability to selectively target pathogenic Aβ oligomers without unproductive binding to non-toxic monomers or plaque.
  • “We believe these encouraging data help differentiate our lead therapeutic candidate, PMN310, from other Aβ-directed antibodies.

ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference

Retrieved on: 
Tuesday, August 2, 2022
TSX, Surface plasmon resonance, Antibody, GLOBE, Donanemab, Solanezumab, Amyotrophic lateral sclerosis, PROMIS, Neurodegeneration, Neuroscience, Edema, PD, Disease, Plaque, Intention, Risk, Conference, Epitope, Crenezumab, ALS, Company, Patient, Toronto Stock Exchange, PMN, Nasdaq, Poster, San Diego Convention Center, Therapy, SPR, Vaccine

The binding of multiple A-directed antibodies to synthetic oligomers with and without pre-exposure to competing monomers, was evaluated by surface plasmon resonance (SPR).

Key Points: 
  • The binding of multiple A-directed antibodies to synthetic oligomers with and without pre-exposure to competing monomers, was evaluated by surface plasmon resonance (SPR).
  • This characteristic was shared by other A antibodies that have shown positive clinical outcomes, such as donanemab, lecanemab and aducanumab.
  • The narrated poster presentation will be available on the ProMIS website www.promisneurosciences.com after the AAIC closes on August 4, 2022.
  • ProMIS Neurosciences lead therapeutic candidate, PMN310, is a monoclonal antibody for Alzheimers disease created with a novel, proprietary method for generating and developing antibodies that can uniquely and precisely target toxic forms of otherwise normal proteins.

Global Alzheimer Drugs Market Report 2022: Cholinergic, Memantine, Combined Drugs, Market Insights, Pipeline and Forecasts, 2017-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 8, 2022
Health, Pharmaceutical, Obesity, Eli Lilly and Company, Prevalence, Combination drug, Novartis, Novo Nordisk, Traction, Research, Company, AbbVie, COVID-19, Global, Pharmacy, USD, Biogen, Pfizer, Diabetes, Market share, Smoking, Disease, BP, Degenerative disease, Memantine, Cholinergic, Takeda Pharmaceutical Company, Pharmaceutical industry, Fine chemical, Dietary supplement, Alzheimer's disease, Solanezumab, Aducanumab

The "Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Alzheimer Drugs Market (2022 Edition) - Analysis By Drug Class (Cholinergic, Memantine, Combined Drugs, Others), Distribution Channel, By Region, By Country: Market Insights, Pipeline and Forecast with Impact of Covid-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Alzheimer Drugs Market was valued at USD 6537.0 Million in the year 2021.
  • Moreover, the increasing prevalence of Alzheimer's disease is fueling the demand for Alzheimer's drugs which in turn is driving the global Alzheimer's drugs market.
  • Also, rising R&D activities by pharmaceutical companies and research institutes for Alzheimer's effective therapy is expected to boost the global Alzheimer's drugs market.

Global $200+ Bn Central Nervous System Therapeutic Markets to 2028 - Introduction of a Novel Drug Delivery Systems / Presence of Strong Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 6, 2021
Health, Pharmaceutical, CNS, Trauma, Therapy, Cancer, Neurodegeneration, USD, Epilepsy, WHO, Central nervous system, National Cancer Institute, MD Anderson Cancer Center, Parkinson's disease, Depression, Amyotrophic lateral sclerosis, Death, Solanezumab, Alzheimer's disease, Alembic Pharmaceuticals, Mental health, Lists of diseases, Acquisition, Company, Growth, Multiple sclerosis, Prevalence, Eli Lilly and Company, Ionis Pharmaceuticals, Migraine, Brain, Anxiety, Government, Schizophrenia, Pharmaceutical industry, Oil

High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period.

Key Points: 
  • High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period.
  • In February 2020, Biogen announced the investment in Sangamo's zinc finger platform to develop therapies for Alzheimer's disease and other neurological diseases.
  • Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.
  • Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients

Retrieved on: 
Thursday, January 21, 2021
Health, Managed care, Clinical trials, General Health, Pharmaceutical, Biotechnology, Clinical research, Branches of biology, Medical research, Health sciences, Design of experiments, Placebo-controlled study, Alzheimer's disease, scyllo-Inositol, Solanezumab, AR1001, AR1001-ADP2-US01, AriBio Co., Ltd.

AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimers disease.

Key Points: 
  • AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimers disease.
  • Despite the challenges presented by the COVID-19 pandemic, we were able to complete dosing and follow-up assessments in this trial.
  • AriBio is the first company from South Korea to successfully complete a Phase 2 study for Alzheimers disease in the United States.
  • AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease.

Alzheimer's Disease Market and Forecast Analysis 2034: Solanezumab's Failure will Likely Impede the Uptake of Future Beta Amyloid Antibodies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 18, 2019
Health, Pharmaceutical, Branches of biology, Psychiatric diagnosis, Cognitive disorders, Psychiatry, Medicine, Learning disabilities, RTT, Alzheimer's disease, Dementia, Neurodegeneration, Solanezumab, Amyloid

The "Alzheimer's Disease Market and Forecast Analysis 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alzheimer's Disease Market and Forecast Analysis 2034" report has been added to ResearchAndMarkets.com's offering.
  • Alzheimer's disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function.
  • Alzheimer's disease is the most common cause of dementia among older people.
  • Solanezumab's failure will likely impede the uptake of future beta amyloid antibodies.